Ropivacaine Plasma Concentrations and Pharmacokinetics Following Erector Spinae Plane Block in the Pediatric Population

PHASE4CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

December 18, 2020

Primary Completion Date

January 27, 2021

Study Completion Date

March 29, 2021

Conditions
Anesthesia, Local
Interventions
DRUG

Ropivacaine

Given the reproducible efficacy of the erector spinae plane block for thoracic procedures, this pilot study will recruit patients scheduled to undergo thoracic surgery with the adjunct of an erector spinae plane block for perioperative pain. Participants will be assigned sequentially to either ropivacaine 0.2% at 0.3ml/kg or ropivacaine 0.5% at 0.3ml/kg.

Trial Locations (1)

77030

Texas Children's Hospital, Houston

All Listed Sponsors
lead

Baylor College of Medicine

OTHER

NCT04298099 - Ropivacaine Plasma Concentrations and Pharmacokinetics Following Erector Spinae Plane Block in the Pediatric Population | Biotech Hunter | Biotech Hunter